Robert B. Junker - 01 Oct 2021 Form 4 Insider Report for LYDALL INC /DE/

Source evidence Original filing metadata and source links for verification. 3 source fields
SEC form
4
Accepted by SEC
05 Oct 2021, 12:40:33 UTC
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
Chad A. McDaniel attorney-in-fact for Robert B. Junker

Key filing fact

Robert B. Junker filed Form 4 for LYDALL INC /DE/ on 05 Oct 2021.

Key facts

  • This page summarizes Robert B. Junker's Form 4 filing for LYDALL INC /DE/.
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 05 Oct 2021, 12:40.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LDL transaction

Common Stock

Award

Transaction value
$0
Shares
+9,298
Change %
+30%
Price
$0.000000
Shares after
40,200
Date
01 Oct 2021
Ownership
Direct
Footnotes
F2, F3
LDL transaction

Common Stock

Disposed to Issuer

Transaction value
Shares
-40,200
Change %
-100%
Price
Shares after
0
Date
01 Oct 2021
Ownership
Direct
Footnotes
F1, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LDL transaction Derivative

Non-Qualified Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares
-23,592
Change %
-100%
Price
Shares after
0
Date
01 Oct 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
23,592
Exercise price
$19.60
Footnotes
F5
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Robert B. Junker is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 5 footnotes

Footnote F1

Disposed of as a result of the merger pursuant to the previously announced Agreement and Plan of Merger, dated as of June 21, 2021, by and among Lydall, Inc., Unifrax Holding Co., Outback Merger Sub, Inc. and Unifrax I LLC, as it may be amended from time to time, referred to as the Merger Agreement.

Footnote F2

Represents an increase from the number of Performance Shares granted under the Company's Amended and Restated 2012 Stock Incentive Plan on each of November 1 ,2019 and February 22, 2021 following the certification, on October 1, 2021, by the Board of Directors of the attainment of the performance criteria set forth in the award in excess of target. The shares covered by this report, as well as the original 8,546 and 5,025 shares underlying the awards previously reported on the above dates vested in full on October 1, 2021 and were converted in the Merger into the right to receive $62.10 in cash per share underlying the Performance Shares (the "Merger Consideration").

Footnote F3

Previously reported Restricted Stock and Performance Share awards were included in previously reported amount of securities beneficially owned.

Footnote F4

Each share of common stock was cancelled pursuant to the Merger Agreement in exchange for the right to receive the Merger Consideration.

Footnote F5

Effective as of immediately prior to the effective time of the Merger, each then-outstanding and unexercised stock option of the issuer with an exercise price less than $62.10 was automatically canceled and converted into the right to receive an amount of cash equal to the product of (i) the total number of shares of Common Stock then underlying such stock option multiplied by (ii) the excess of the $62.10 over the exercise price per share of such stock option, on the terms set forth in the Merger Agreement.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .